Ikonisys Announces That Hospitex International Won the Public Tender of the Prestigious U.O.C. Pathological Anatomy of Enna in Italy
10 Octobre 2024 - 7:30AM
Business Wire
Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a company
specializing in the early and accurate detection of cancer through
fully automated solutions for medical laboratories, is pleased to
announce that its fully-owned company Hospitex International has
successfully won the public tender for the in-service supply of
diagnostic systems to the U.O.C. Pathological Anatomy Unit in Enna,
Italy.
This tender follows the launch of an open procedure for the
in-service supply of diagnostic systems intended for the Public
Health Laboratory Unit and the U.O.C. Umberto 1st Pathological
Anatomy Unit in Enna.
The contract includes the full in-service supply of its CYTOfast
system with a total value nearing €400.000 based on price/quality
parameters.
During a public session, the commission reviewed administrative
and technical documentation to assess compliance from participating
companies. This new milestone once again highlights Hospitex’s
ongoing dedication to delivering innovative and efficient solutions
for early cancer diagnosis.
Francesco Trisolini, COO of Ikonisys and CEO of Hospitex,
stated: “This achievement is a significant step for Hospitex
International, reaffirming our commitment to improving diagnostic
accuracy and streamlining the diagnostic process. We are excited to
continue combining our expertise and positioning our companies as
leaders in cancer diagnostics”.
This Public Tender represents an opportunity for Ikonisys Group
to position on major projects.
About Hospitex International
Hospitex International is the world leading company for cytology
standardized monolayer preparations. With CYTOfast it has
re-invented the cytological diagnostics. Hospitex offers a full
range of integrated solutions aimed at streamlining diagnostic
processes in cytology. The global shortage of expertise in
pathology requires tools and technologies that enable diagnostic
safety, efficiency and capacity building. In this area, Hospitex is
recognized as the precision diagnostics player in cytology.
For more information: https://www.hospitex.com/en/
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated
solutions designed to deliver accurate and reliable detection and
analysis of rare and very rare cells. Ikonisys has received FDA
clearance for several automated diagnostic applications, which are
also marketed in Europe under CE certification. Through its
breakthrough fluorescence microscopy platform, the company
continues to develop a stream of new tests, including liquid biopsy
tests based on Circulating Tumor Cells (CTC).
For further information, please go to
www.ikonisys-finance.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241009362220/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024